Krystal Biotech (KRYS) Financial Analysis & Valuation | Quarter Chart
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullo... more
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gen... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $9.48B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Krish S. Krishnan |
| IPO Date | 2017-09-20 | CAGR | — |
| Employees | 295 | Website | www.krystalbio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KRYS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $10.57B | P/E | 40.12 | Forward P/E | 35.99 | PEG | 1.04 |
| P/S | 402.2 | P/B | 130.86 | P/CF | 652.27 | P/FCF | 687.54 |
| Sales | $440.48M | Sales 1Y | 22.63% | Sales 3Y | inf% | Sales 5Y | inf% |
| EPS | $7.98 | EPS 1Y | 62.2% | EPS 3Y | -246.96% | EPS 5Y | -420.48% |
| Sales QoQ | 2.46% | EPS QoQ | -2.19% | Sales QoQ Avg | 5.61% | EPS QoQ Avg | 18.89% |
| Gross Margin | 67.73% | Operating Margin | 44.93% | Profit Margin | 54.82% | ROCE | 14.41% |
| ROA | 16% | ROE | 19% | Altman Z Score | 44.33 | Piotroski Score | 4 |
| Current Ratio | 8.32 | Quick Ratio | 7.96 | Cash Ratio | 3.36 | Op. CF Ratio | 0.59 |
| Debt/Equity | 0 | Debt/Assets | 0 | Lt Debt/Equity | — | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | 0.5 | Asset Turnover | 0.29 | Receivables Turnover | 3.18 |
| Enterprise Value | $10.57B | P/E Ratio | 40.12 |
| Forward P/E | 35.99 | PEG Ratio | 1.04 |
| P/S Ratio | 402.2 | P/B Ratio | 130.86 |
| P/CF Ratio | 652.27 | P/FCF Ratio | 687.54 |
| EPS | $7.98 | EPS Growth 1Y | 62.2% |
| EPS Growth 3Y | -246.96% | EPS Growth 5Y | -420.48% |
| Revenue Growth 1Y | 22.63% | Gross Margin | 67.73% |
| Operating Margin | 44.93% | Profit Margin | 54.82% |
| ROE | 19% | ROA | 16% |
| ROCE | 14.41% | Current Ratio | 8.32 |
| Quick Ratio | 7.96 | Cash Ratio | 3.36 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 44.33 | Piotroski Score | 4 |
Krystal Biotech (KRYS) valuation & financials
Krystal Biotech (KRYS) has a market capitalization of $9.48B and trades at a price-to-earnings ratio of 40.1. It operates in the Healthcare sector (Biotechnology).
Krystal Biotech's revenue grew +22.6% over the last year.
Krystal Biotech's next earnings report is scheduled for November 2, 2026 (provider scheduled date); analysts estimate EPS of $1.84. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)